Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They don’t even have enough cash to make it to their estimated CLI trial completion of May 2020, even with cash saving contingency plan in place. And we all know May of 2020 would be unlikely even for half to be completed with 1 year of follow up. Partners? LMBO!!!
It’s all coming down to the next quarter or two max. Will they survive, or die?
Did we actually see anything new? What about all the secondary measures from their presentation? One thing I notice. Conflict of interest for Norbie...significant.
Glad you find the dire financial situation and the loss of jobs hilarious. Sadly it’s not. Should get a whole flurry of made up stuff today to try and hide how bad their situation is. Will keep posting it to make sure it’s there front and Center, with real numbers not one skewed by an accountant.
Updated Financials.
Kaki has made this job easier with the big update he made. But I’ll expand on his numbers since the accountant wanted to conveniently omit some important info regarding cash they have access to.
Kaki’s all cash and grant money remaining. $22.5 mil.
Liabilities. $7.4 mil
Leaving out another $2 mil in long term liabilities.
Grand total $15.1 mil remaining as of Sept 30th. Here we are almost half way through the next quarter, so how much now. Just using Kaki’s statement of $8.5 mil used last quarter, it’s easy to see we are a long way from having enough to make it to 2020.
Yes cost cutting measures have been put into place. Question is, when does the cash saving contingency plan kick in? They going to wait until under $10 mil...$5 mil?
They are in quite a predicament, that’s for sure. So bad that Kaki has to spew some garbage of an additional $7.5 mil in “resources”. What the hell is that? Is this a new financial term I’m not aware of? Kaki utilizing accounting liberties. Did I miss these resources in their filing? It’s one thing. DESPERATE!!!!
Unfortunately I don’t think the job cuts that have/are coming doesn’t make employees at Pluristem ecstatic. And any long position in this stock surely doesn’t make anyone ecstatic. Only ones who are truly ecstatic are the twins and how much they’ve milked from shareholders out of over all these years.
Only good thing about all of this is we will see soon enough if company will survive, or if the lights will go out.
The rest is for all the other parties involved. Our burn rate is what it is regardless of how much remains for the other parties. What happens to our burn when they use all the funds allocated to them. We just had manufacturing costs which are minimal I’m sure. And paying for all our employees and rent and such. I’d imagine the costs others incur to actually run the trials would burn through their portion pretty quickly. That’s why for them to think these grants would cover most of the costs for these trials was a joke. It’s not.
And yes we will see what this new data brings. Hopefully better than the last several duds. But not counting on it. Again brings the question of if other data becomes relevant to the FDA if not listed in trial design. Also better see some serious statistically relevant data as well. Edison’s latest report sure picked apart the statistical flaws in the top line results.
Is this the link to your new found optimism. MedCity from London. Great find. LMBO.
https://www.bioportfolio.com/news/article/3811063/MedCity-sets-up-advanced-therapy-research-network.html
Any new thoughts on the financials? Was my DD ok? Pretty dire situation they seem to be in don’t you think?
Is there a European company opening shop in Haifa? Not in Matam Park is it? Ohhh it’s so exciting. Maybe they’re even going to sublease a portion of Pluristem’s space!!! I guess one could construe that as a “partnership” of sorts. Fingers crossed again!!!
Continue to answer all the questions? LMBO. Following analyst reports, some with wrong financial information, and their buy recommendations that go along with it, is hardly an answer. Hey don’t you leave the financial numbers to them as well. LMBO. I see strong buy is back on the table. LMBO. Basing your “investing” on charts, analyst reports, and analyst recommendations on a stock like this leave you with 2 things. Hope and Prayer.
I can see why it’s hard to find. Conveniently it gets left out of current reports. As far as Maxim, that’s what you get when you listen to the “pros”. Pluristem only gets a portion, but if you look at any presentation or update, they want you to think they get it all. Why?
https://www.sec.gov/Archives/edgar/data/1158780/000117891318000390/zk1821111.htm
In August 2016, our CLI program in the European Union was awarded a Euro 7,600,000 (approximately $9,100,000) grant. The grant is part of the European Union’s Horizon 2020 program. The Phase III study of PLX-PAD in CLI will be a collaborative project carried out by an international consortium led by the Berlin-Brandenburg Center for Regenerative Therapies together with us and with participation of additional third parties. The grant will cover a significant portion of the CLI program costs. An amount of Euro 1,900,000 (approximately $2,300,000) is a direct grant allocated to us for manufacturing and other costs, and we also expect to have direct benefit from cost savings resulting from grant amounts allocated to the other consortium members. In July 2017, the consortium amended the consortium agreement, pursuant to which the original grant allocation has been amended such that we will receive an additional direct grant of Euro 1,000,000 (approximately $1,200,000). The additional direct grant was allocated to us from the total amount of the original grant.
In September 2017, our Phase III study of PLX-PAD cells to support recovery following surgery for femoral neck fracture was awarded a Euro 7,400,000 (approximately $8,900,000) grant. The grant is part of the European Union’s Horizon 2020 program. The Phase III study of PLX-PAD to support recovery following surgery for femoral neck fractures will be a collaborative project carried out by an international consortium led by Charite Universitätsmedizin Berlin, together with us, and with participation of additional third parties. The grant will cover a significant portion of the project costs. An amount of Euro 2,400,000 (approximately $2,900,000) is a direct grant allocated to us for manufacturing and other costs, and we also expect to have a direct benefit from cost savings resulting from grant amounts allocated to the other consortium members.
In October 2017, the nTRACK, a collaborative project carried out by an international consortium led by LEITAT, was awarded a Euro 6,800,000 (approximately $8,000,000) non-royalty bearing grant. An amount of Euro 500,000 (approximately $600,000) is a direct grant allocated to us. We also expect to benefit from cost savings resulting from grant amounts allocated to the other consortium members.
Yes and can’t wait to see the interim HCT results in 2H17!!! Fingers crossed!!! Go Tobesters!!! Kaki is Happy!!! NO BAD NEWS!!!
No worries...Nothing to see here...ALL IS WELL. ALL IS WELL.
LMBO. I’m sure your mousepad would have the logo on it and a wrist rest. Nothing but the best for them. I’ve heard they’re quite frugal with shareholder money.
Seriously though I’m not predicting doomsday just yet. Just pointing out their dire situation on the financial side. Don’t like when people mislead, and when the co-ceo comes out and states a misleading statement like they did, I’ll make sure to give the real facts.
I’m quite sure it’s a standoff of sorts. Do a raise soon, or hope funding for ARS pivotal trial comes through. Twins want to get their hands on their share of the non dilutive funding pie. Everyone’s hoping for their half mil bonus on a potential $50 mil government funding. Just Hope and Pray they don’t hold out too long. At least at these prices, $20 mil would mean a 20 mil share increase. Or 30 mil if warrants are attached. Hate to see what would happen if we drift under a buck. Time will tell. Year end clock is a ticking.
We are supposed to get funding and finally get the pivotal study started by year end. But maybe, just maybe, the trials won’t be necessary and we will jump right to approval like one here suggests. LMBO.
Taken from Zami’s last appearance on updates to shareholders. Mind you I do seem to recall seeing this being updated again since February, showing 2H18/1H19. Delays and missed milestones are the twins mo. Here’s to Hoping and Praying it comes before the lights are turned out. That time is approaching quicker than I imagined. Maybe they’ll become a skeleton staff of 2 at one point to allow the company to survive. Full pay of course.
“In our Acute Radiation Syndrome (ARS) program, following the positive results from the Phase II- equivalent study in non-human primates, which was conducted by the National Institutes of Health (NIH), we are in discussions with the FDA and several U.S. governmental agencies to clear the path for a pivotal study. This process includes several complementary studies, the majority of which are funded and conducted by the NIH, which will also provide additional data to support future milestones. We expect to collect the complementary data during the first half of 2018 and to clear the pivotal study protocol and funding during the second half of 2018. We are also collaborating with the U.S. Department of Defense’s (DOD) Armed Forces Radiobiology Research Institute (AFRRI), to examine the effectiveness of PLX-R18 as a treatment for ARS prior to, and within the first 24 hours of exposure to radiation. These studies are conducted and funded by AFRRI and we expect to receive data from these studies in 2018.”
Again why do they leave the accounts payable side of the equation out of the update. They have $7.4 mil owing, so pretty misleading don’t you think? Maybe not paying their payables is them initiating their cost reduction plan.
Funny how in the quarterly, they state they have $21,716,000 left. Now WITH the grant money remaining, it brings them up to $22.5 million. See my calculations on the remaining grant money was pretty much spot on. So see, IT IS TRUE. That’s the thing about public companies, you can find it with a little effort. Or just close your eyes and Hope and Pray. Leave it to the “pros”. Lmbo.
These are the reasons to remain “ok with them”. Try and spin it all you like. These guys have been way over their head from the beginning. All they cared about was promoting themselves to get bigger paycheques and more free shares. Wonder if they took pay cuts yet, or will it be full pay for those at the top until the bitter end. Milk every penny they can.
Wonder what big move they will make in desperation. Was going it alone a good idea? Unfortunately I think that was their only choice.
Is ANYONE else now not “ok with them”.
And there we go, the big update. Just when I thought he couldn’t be any dumber, Yaki comes out with a new update, and totally redeems himself. !!!
““Importantly, the FDA approved reimbursement for the procedure with a cost recovery that may provide a key reference point for eventual commercial pricing”
What it that? Glad they will get a reference point for pricing from this risky endeavour. Oooohhhh ahhhhh. The crowds going crazy.
Making “good progress”. They still can’t ever give numbers. I guess because they’re too “good”.
“30 million in resources”. Are they planning to sell some office chairs, cubicles, desks, laptops? Maybe a couple bioreactors. Hey if you bought this stuff for a million bucks you should be able to sell it for a million right.
Not a peep about US government. It will come when it comes. Don’t worry, we got 180 office chairs to sell.
Great update!!! LMBO
How come you don’t call out the one who posts about strong buy ratings 20 times, even though they’re shown otherwise the first time? Fictitious correct calls on TA, proven false with direct quotes and links? No understanding of conflicts if interest when it comes to analyst ratings? Fake insider buys? Fake tute numbers?
The next week Betty Lou calls for the last 10 years? Next month calls? Next quarter calls? Lonza call because they set up in Haifa? Latest AZ prediction? Made up calls we are the only one who can manufacture MSC’s? All the cash in the world to jam as many 75L 3D bioreactors as possible, so we can make cells for nobody?
Quote after quote with remarks that have old age homes in Britain, busting with newfound laughter? Great scientists? Tobias? No bad news?
Missed milestone after milestone? Cost cutting measures being engaged? Next stop, contingency plan? Zero experience? 2 ceo’s Company puts one endpoint in trial design, then puts more in presentation? Millions of shares as bonuses? Raises? Dilution event after dilution event. ATM? Share price?
How come no complaints for any of these? People with actual skin in the game aren’t Happy with how this company looks, should I say looked, after their own and only their own. Pretty justifiable when you have many claiming Happy times ahead, great time to buy. Anything under $2 is a steal. Still believes it to this day. Think I’ll have to go buy some several blocks of 25k shares too. No risk here.
Or it because it goes against the way many here seem to “invest”. On Hope and Prayer. But you are right. Time does have value. I do waste way too much time here yet again, with little to no avail.
Here’s some more financial info. Notice the increasing expenses year after year. One thing to take note from the numbers below. The G&A expense just on their new report, has a sudden decline of $600k. It would seem as though they have started to slash jobs. Guess Ohad kindly picked them up.
One other thing to note. There is a line on the long term asset section for severance pay fund. It stands at $858k. With the Israeli severance pay being 1 month salary/year of employment, I would imagine there will be a decline in that fund.
I would imagine that fund would have to be replenished, which would then be taken from their cash side. Let enough of them go, could have an impact. The joys of having 180 employees.
Wanted to finally act like a big man and be in charge of a big company. Still got that swagger in your step walking around the office. Feel good to be letting people go? People scared now when you call them into your office. I’m sure it’s just a small office right. Big jump from Elbit wasn’t it. First aid kits easier? Espresso bar still stocked? Promoting and accountant to help you out in your duties work out well for you? Did catered lunches end? Felt good didn’t it Zami. You were the MAN!!! All at the expense of shareholders.
But make no mistake about it, they seem to be letting people go. Not good for a company expecting a stockpiling agreement by the end of 2017. So glad the board approved Zami’s raise. Poor guy didn’t get one since 2011.
Quarter ended Sept/17
G&A expense $2,763 mil
R&D expense $5,192 mil
Quarter ended Dec/17
G&A expense $2,920 mil
R&D expense $6,259 mil
Quarter ended Mar/18
G&A expense $2,666 mil
R&D expense $7,481 mil
Quarter ended June/18
G&A expense $2,844
R&D expense $7,439
Quarter ended Sept/18
G&A expense $2,210
R&D expense $7,765
Care to expand on what’s not true? The amount of grant money they’ve used? The amount they received? The dismal amount of cash they have left? They are in a bad situation right now. Another dilution will be coming real soon. Let’s see if it was just fools buying before the quarter or and orchestrated bump. Some still Hope since they don’t understand financials. Might be a good thing. Crying would start early.
Edison is paid by TASE to rate listed companies. No conflict there. LMBO. Hope and Pray...
I’ll give you a quarter this time. If they wait another 9 months or so, they could get the whole company for pennies on the dollar. Sure they’ll even throw in Kaki and his pocket for good measure. Hope and Pray that doesn’t happen eh.
You must have missed my five previous posts on the topic of grants where only two replied, one begrudgingly. Here it is again. Just the grant part. This was from last quarter, so take a mil off of what’s left. $1.1 mil in direct cash to Pluristem left. Funny... you sound like their presentation.
Now in their last report, in the last 3 years they have used approximately $9.9 mil of their grants from Horizon and IIA. They were directly receiving $6.4 million from the Horizon,
Grants.
$6.4 million direct from Horizon
$3.3 mil IIA 2016
$1.4 mil IIA 2017
$900 g’s IIA 2018
$12 million total.
Wow wee. Is that why all the big guns that have the cash and knowledge to beat small companies to the finish line are everywhere in this field now? If there was something Pluristem had that was of such significance, we would have been gobbled up long ago. But here we stand with $17 mil left. Chances of success get better with each passing quarter.
Not really sure if any of the secrecy matters. All one has to do is look at the last quarter of ‘17 where they sold $50k at a cost of $2k. I would imagine Widetrials and their cut would try and skew those numbers. But pointless if you ask me.
A funny note too. Edison report states they expect revenue in 2020 from stockpiling of ARS by US. It’s weird they state they only use public information to guide their analysis. Something tells me they got some fort of confirmation from somewhere else. Certainly not from what the company told us.
And if you look at all the holes Edison points out in their top line IC assessment, we better hope for some better results on the soon to be released data. With statistical significance. You were the one to point that out if I’m not mistaken Auto.
Another thing with the Edison report. They make the point how there was only one endpoint as well. I guess that’s why we never heard back from Spidey on whether an endpoint listed on a presentation is suitable for the FDA to take it into account or not.
Another “experience not necessary” moment from the goon squad.
If you look, they have $24.4 mil of cash, and $7.4 mil in liabilities. So it’s actually $17 million left in the bank. Last quarter they had $23.5 mil left.
They did use another $1 mil in grant money to offset expenses. That leaves them with about $1 mil in grant money left.
So this situation is getting worse with each quarter that passes. I was thinking they could be down to around $15 mil by eoy, but looks like we will be closer to $10 mil. If someone here is NOT concerned about this, they better get Praying, in the Hope the analysts will be right. Otherwise the Blubbering will begin.
It’s funny too that I knew those employees from Pluristem weren’t on Ohad’s Site before. These were fresh marks on their arses.
Look on the bright side. We should be getting a presentation, or a shareholder update any moment now. We deserve it!!! Fingers crossed!!!!
It’s not about the money but the item not being reported in the year end report. It does mention the “grant” but nothing about the grant having to be paid back via royalties. One would almost think it was free. Wonder if the clowns took their piece of the “non dilutive” funding, even though it has to be paid back.
Actually it is there in previous quarterlies. At least the Sourasky royalties. But magically disappeared from the year end. And haven’t found the one giving 5% royalty for assistance in China market. Stinks no matter what.
Where’s the mention of the 5% royalty huh? Jokes
No mention of either nice try. It is new. Just do a search of Sourasky. Only shows an agreement. No details. Funny the news release mad no mention of payment of royalties on it either.
Here’s another new piece of dirty laundry. Why oh why is all this stuff coming out now. Seems they’re offering royalties to everyone. Only one I knew of before was Israeli government.
“The Company will also receive close support from Israel’s trade representatives stationed in China, including Hong Kong, along with experts appointed by the Smart Money program. As part of the program, the Company will repay royalties of 5% from the Company’s revenues in the region for a five year period, beginning the year in which the Company will not be entitled to reimbursement of expenses under the program and will be spread for a period of up to 5 years or until the amount of the grant is fully paid”
Funny that was brought to the attention of the board just last month. Nobody seemed to care then
Funny here I thought Sourasky was just interested in us. Why was there no mention of this royalty payment before. Seeing quite a few new things in here that I’ve never seen before. Airing of some dirty laundry, now that cash conservation plan is now active.
“As part of the agreement with the Tel-Aviv Sourasky Medical Center (Ichilov Hospital), the Company will pay royalties of 1% from its net sales of the PLX-PAD product relating to GvHD, with a maximum aggregate royalty amount of approximately $250”
Cash situation is garbage thanks. And here’s a quote. Told you employees were dumped.
“The Company is addressing its liquidity issues by implementing initiatives to allow the continuation of its activities.”
Still “ok with the clowns”. How bout a pay cut for the bozos on top. Disgusting!!!
I like most, understand the “role” of “professional” analysts when it comes tfrom stocks like ours. I’m sure most give their ratings 4+ years out. Those that don’t understand their role, rely on Prayer, then downright blubbering.
Accumulation? LMBO. How many times have I heard that. Right up there with analyst recommendations. Laughing so loud one could almost accuse me of crying. I leave that one for the ones that hope and pray these analysts will make a correct call for once. Maybe even a proprayster. Or a propraycryster. The investor cycle for the uneducated, that rely on analyst recommendations. It’s just that easy!!!
How have we managed to bounce and stay approximately 10% off our newly established 52 week low? On 5 days of pathetic volume. Did I miss a news event? Is this going to be the range we made it to for our next dilution? Or will we see some more upside movement if we ever get some more fluff news. It’s a good start but is that all you got? Cmon analysts, show your skills and woo Zami for your payday. Let’s all prayster.
Have a look at H.C. Wainwright’s calls over the years. Pretty accurate aren’t they. Almost as accurate as a chart. Let us all prayster that this year will be the year of the analyst. All BUY calls Btw. LMBO. Too easy!!!
2018 $3.50 target
https://www.tickerreport.com/banking-finance/3825028/hc-wainwright-reaffirms-buy-rating-for-pluristem-therapeutics-psti.html
2017 $3.50 target
http://www.markets.co/h-c-wainwright-sticks-to-their-buy-rating-for-pluristem/
2016 $3.50 target
https://www.streetinsider.com/dr/news.php?id=11840801
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -5.7% and a 34.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as X T L Biopharmaceuticals Ltd (ADR), Strata Skin Sciences Inc, and Spectrum Pharmaceuticals.
2015 $4 target
https://ca.proactiveinvestors.com/companies/news/105556/pluristems-cardiovascular-programs-remain-primary-value-driver-hc-wainwright-59944.html
2014 $4 target
https://www.streetinsider.com/dr/news.php?id=9813107
A 3 year delay to start a “fast tracked” trial is pretty franted I must say. Came straight from management so if there’s anyone to blame for a franted statement, please contact Karine. And here’s another kicker. Wonder how much they paid to acquire the rights to use this patent in Japan in April of 2016. Money well spent I’m sure. Good thing franted was changed to distorted. Pretty embarrassing. That’s what management is good at, distorting everything.
Funny you look back on all the releases over the years and it’s a joke. It truly is. Full of direction changes, miss after miss. Silence on so many things that were going to get started.
And another reason to be “ok with them”.
Should be seeing a Prayster handle soon. LMBO. You can’t make this stuff up!!! Management sure does though. On pretty much everything.
http://www.pluristem.com/wp-content/uploads/2016/04/TES_PatentPurchase_Final.pdf
Almost 3 years of silence. We should be starting any day now. Glad we have fast track in Japan. And partners are knocking hard. Can’t wait. Maybe Japan isn’t even wanting to do the trial. They just want it now!!! Maybe it’s top secret. Maybe US government stepped in and said no, we got this. Is Lonza in Japan? At least a couple are Hoping. They love hope and potential. LMBO
Another reason to be “ok with them”.
Pluristem Reaches Agreement with Japan’s PMDA on Protocol for Final Trial Targeting Market Entry via Accelerated Pathway
? The agreement is expected to accelerate discussions with potential Japanese partners
? The study will include 75 patients and a 9 month follow-up
HAIFA, ISRAEL, December 21, 2015 -- Pluristem Therapeutics Inc. (NasdaqCM / TASE: PSTI), a leading developer of placenta-based cell therapy products, today announced that it has reached an agreement with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) on the design of the final trial needed to apply for conditional approval of PLX-PAD cells in the treatment of critical limb ischemia (CLI). The approval of the protocol for the 75-patient trial was part of a larger agreement on the development of PLX-PAD via Japan’s new accelerated regulatory pathway for regenerative medicine.
“With this achievement we have advanced our strategy to expedite commercialization of our cell products. Pluristem is now positioned favorably to accelerate negotiations with those Japanese pharma companies interested in becoming dominant players in the expanding regenerative medicine market in Japan,” stated Pluristem Chairman and CEO Zami Aberman.
The trial will collect data on 75 patients suffering from CLI. These patients will be randomized into three groups of 25. Group one will receive an initial 150 million PLX- PAD cell dose followed eight weeks later by a second 150 million cell dose; group two will be treated with an initial 300 million PLX-PAD cells followed eight weeks later by a second dose of 300 million cells; group three will receive two doses of placebo. The cells will be injected into a leg muscle using a standard syringe. Efficacy and safety will be determined from outcomes measured nine months after administration of the first dose. The primary efficacy endpoint will be diagnosis of a patient as CLI-free for 60 days. Pluristem expects to submit the formal Clinical Trial Notification (CTN) to the PDMA,
based on the agreement reached with the regulatory body, in early 2016. The PMDA is expected to respond officially within 30 days. Earlier in 2015, the PMDA cleared PLX- PAD cells for use in clinical studies in Japan, a prerequisite to conducting this clinical trial.
About Japan’s Conditional Time-limited Approval for Regenerative Medicines
Japan’s Act on the Safety of Regenerative Medicines went into effect in November 2014. Its purpose is to facilitate faster approval of cellular therapies and other regenerative medicine treatments for marketing. According to the law, these therapies can receive conditional, time-limited approval for marketing, and be eligible for reimbursement, upon proof of safety and a signal of effectiveness but prior to verification of efficacy. Safety and efficacy need to be confirmed via collection of observational data after the conditional approval.
Celularity has been proven to be no concern at all. All of the new adaptive pathways out there are useless. We have had them for many years, and what has that bought us. They won’t be able to utilize them at all, just like us. Experience is irrelevant after all.
Some quotes from the May 2015 Letter to Shareholders. Sure seems to me 12 months have passed. But look on the bright side...we have under 2 months to go before CLI “enters the market”.
At least before they gave 4 pages of info on their “progress”. You’d think with all the “progress” we would get more than 2 pages of info like we do now. But this year will be different. LMBO
Just another great reason to be “ok with them” and proves “experience is not necessary”. And great reasons to still have “Hope”. LMBO
http://www.pluristem.com/wp-content/uploads/2016/05/Pluristem-CEO-Letter-May-25-Final.pdf
“Pluristem continues working to establish additional business collaborations with pharmaceutical companies. The new opportunities in Europe and Japan have translated into substantial interest from potential partners who would like to work together with us in both geographic regions. We are hopeful that we will achieve additional partnership for our CLI program over the next twelve months, and are also discussing partnerships for our muscle injury program and our emerging clinical program for PLX-R18, our second product.”
“Advancing a partnership with a pharmaceutical company to partner our CLI and/or Muscle injury programs.”
“when we discuss our anticipation that PLX- PAD cells could enter the market in 2018 to treat patients with the clearly defined subtype of CLI studied in the trial, when we discuss achieving additional partnership for our CLI program over the next twelve months”
Yes that picture of the 75L bioreactor and the older Japanese man waving his fist at Zami, have been there forever. Should get an updated presentation before the quarter reports. That way they can show the amount of cash based as of June, so they don’t have to show the real number from September. Funny how they don’t even take away the accounts payable side of that equation. Wouldn’t want to show the true financial woes they’re facing. What about the approximately $50 mil they show as non dilutive grants. Why don’t they state when all those grants are from. Since inception? Not even sure that would add hot to close to that. But hey, maybe they just rounded to the nearest 50k
Just another sign of managements integrity.
And of course, another sign to be “ok with them”.